|
1
|
Ji YT, Liu SW, Zhang YM, Duan HY, Liu XM,
Feng ZW, Li JJ, Lyu ZY and Huang YB: Comparison of the latest
cancer statistics, cancer epidemic trends and determinants between
China and the United States. Zhonghua Zhong Liu Za Zhi. 46:646–656.
2024.(In Chinese). PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI
|
|
3
|
Rami-Porta R, Nishimura KK, Giroux DJ,
Detterbeck F, Cardillo G, Edwards JG, Fong KM, Giuliani M, Huang J,
Kernstine KH Sr, et al: The international association for the study
of lung cancer lung cancer staging project: Proposals for revision
of the TNM stage groups in the forthcoming (Ninth) Edition of the
TNM classification for lung cancer. J Thorac Oncol. 19:1007–1027.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang X, Chen Q, Ren Y, Zhu J, Xu L, Huang
S, Li W and Xu J: Three-dimensional conformal radiation therapy
with concurrent chemotherapy for stage III non-small cell lung
cancer: Protocol for a systematic review and meta-analysis. BMJ
Open. 14:e0907282024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Provencio M, Nadal E, Insa A,
García-Campelo MR, Casal-Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell
lung cancer (NADIM): An open-label, multicentre, single-arm, phase
2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (Eighth) edition of the TNM classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huber RM, De Ruysscher D, Hoffmann H, Reu
S and Tufman A: Interdisciplinary multimodality management of stage
III nonsmall cell lung cancer. Eur Respir Rev. 28:1900242019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robinson LA, Wagner H Jr and Ruckdeschel
JC; American college of chest physicians, : Treatment of stage IIIA
non-small cell lung cancer. Chest. 123 (1 Suppl):202S–220S. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rajappa S, Sharma S and Prasad K: Unmet
clinical need in the management of locally advanced unresectable
lung cancer: Treatment strategies to improve patient outcomes. Adv
Ther. 36:563–578. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Brien M, Paz-Ares L, Marreaud S, Dafni
U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling
M, et al: Pembrolizumab versus placebo as adjuvant therapy for
completely resected stage IB-IIIA non-small-cell lung cancer
(PEARLS/KEYNOTE-091): An interim analysis of a randomised,
triple-blind, phase 3 trial. Lancet Oncol. 23:1274–1286. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Magee DE, Hird AE, Klaassen Z, Sridhar SS,
Nam RK, Wallis CJD and Kulkarni GS: Adverse event profile for
immunotherapy agents compared with chemotherapy in solid organ
tumors: A systematic review and meta-analysis of randomized
clinical trials. Ann Oncol. 31:50–60. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spigel DR, Faivre-Finn C, Gray JE, Vicente
D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R,
Quantin X, et al: Five-year survival outcomes from the PACIFIC
trial: Durvalumab after chemoradiotherapy in stage III
non-small-cell lung cancer. J Clin Oncol. 40:1301–1311. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et
al: Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC. N Engl J Med. 379:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Naidoo J, Antonia S, Wu YL, Cho BC,
Thiyagarajah P, Mann H, Newton M and Faivre-Finn C: Brief report:
Durvalumab after chemoradiotherapy in unresectable stage III
EGFR-mutant NSCLC: A post hoc subgroup analysis from PACIFIC. J
Thorac Oncol. 18:657–663. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Verfaillie S, Lambrecht M, Berkovic P,
Dooms C, Nackaerts K, Van de Velde AS, Vansteenkiste J and Wauters
E: Treatment of unresectable stage III NSCLC: Real world cohort
study and literature review. Cancer Treat Res Commun.
36:1007272023.PubMed/NCBI
|
|
16
|
Spencer A, Williams J, Samuel R, Boon IS,
Clarke K and Jain P: Concurrent versus sequential chemoradiotherapy
for unresectable locally advanced stage III non-small cell lung
cancer: Retrospective analysis in a single United Kingdom cancer
centre. Cancer Treat Res Commun. 29:1004602021.PubMed/NCBI
|
|
17
|
Riely GJ, Wood DE, Ettinger DS, Aisner DL,
Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, et
al: Non-small cell lung cancer, version 4.2024, NCCN clinical
practice guidelines in oncology. J Natl Compr Cancer Netw.
22:249–274. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guégan JP, Peyraud F, Dadone-Montaudie B,
Teyssonneau D, Palmieri LJ, Clot E, Cousin S, Roubaud G, Cabart M,
Leroy L, et al: Analysis of PD1, LAG3, TIGIT, and TIM3 expression
in human lung adenocarcinoma reveals a 25-gene signature predicting
immunotherapy response. Cell Rep Med. 5:1018312024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reck M, Ciuleanu TE, Cobo M, Schenker M,
Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal
O, et al: First-line nivolumab plus ipilimumab with two cycles of
chemotherapy versus chemotherapy alone (four cycles) in advanced
non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open.
6:1002732021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mielgo-Rubio X, Uribelarrea EA, Cortés LQ
and Moyano MS: Immunotherapy in non-small cell lung cancer: Update
and new insights. J Clin Transl Res. 7:1–21. 2021.PubMed/NCBI
|
|
21
|
Melero I, de Miguel Luken M, de Velasco G,
Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME,
Schuler M, König D, et al: Neutralizing GDF-15 can overcome
anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature.
637:1218–1227. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Strum S, Andersen MH, Svane IM, Siu LL and
Weber JS: State-of-the-art advancements on cancer vaccines and
biomarkers. Am Soc Clin Oncol Educ Book. 44:e4385922024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brueckl WM, Ficker JH and Zeitler G:
Clinically relevant prognostic and predictive markers for
immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung
cancer (NSCLC). BMC Cancer. 20:11852020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang
S and Li Y: Targeting the IDO1 pathway in cancer: From bench to
bedside. J Hematol Oncol. 11:1002018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tekguc M, Wing JB, Osaki M, Long J and
Sakaguchi S: Treg-expressed CTLA-4 depletes CD80/CD86 by
trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Proc Natl Acad Scie USA. 118:e20237391182021. View Article : Google Scholar
|
|
26
|
Johnson ML, Cho BC, Luft A,
Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G,
Hussein M, Lim FL, et al: Durvalumab with or without tremelimumab
in combination with chemotherapy as first-line therapy for
metastatic non-small-cell lung cancer: The phase III POSEIDON
study. J Clin Oncol. 41:1213–1227. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reck M, De T, Paz-Ares L, Edmondson-Jones
M, Yuan Y, Yates G, Zoffoli R, Chaudhary MA, Lee A, Varol N and
Penrod JR: Treatment-switching adjustment of overall survival in
CheckMate 227 part 1 evaluating first-line nivolumab plus
ipilimumab versus chemotherapy for metastatic nonsmall cell lung
cancer. Clin Lung Cancer. 25:e362–e368. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hellmann MD, Paz-Ares L, Caro RB, Zurawski
B, Kim SW, Costa EC, Park K, Alexandru A, Lupinacci L, de la Mora
Jimenez E, et al: Nivolumab plus ipilimumab in advanced
non-small-cell lung cancer. N Engl J Med. 381:2020–2031. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herbst RS, Majem M, Barlesi F, Carcereny
E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR,
Winzer L, et al: COAST: An open-label, phase II, multidrug platform
study of durvalumab alone or in combination with oleclumab or
monalizumab in patients with unresectable, stage III non-small-cell
lung cancer. J Clin Oncol. 40:3383–3393. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li MSC, Chan ALS, Mok KKS, Chan LL and Mok
TSK: Next-generation immunotherapy: Igniting new hope for lung
cancer. Ther Adv Med Oncol. 16:175883592413020212024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma X, Zhang Y, Wang S, Wei H and Yu J:
Immune checkpoint inhibitor (ICI) combination therapy compared to
monotherapy in advanced solid cancer: A systematic review. J
Cancer. 12:1318–1333. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mao S, Zhou F, Liu Y, Yang S, Chen B, Xu
J, Wu F, Li X, Zhao C, Wang W, et al: ICI plus chemotherapy
prolonged survival over ICI alone in patients with previously
treated advanced NSCLC. Cancer Immunol Immunother. 71:219–228.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng X, Fang Z, Liu X, Deng S, Zhou P,
Wang X, Zhang C, Yin R, Hu H, Chen X, et al: Increased vessel
perfusion predicts the efficacy of immune checkpoint blockade. J
Clin Invest. 128:2104–2115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Lu W, Chen M, Cai Z, Zhan P, Liu
X, Zhu S, Ye M, Lv T, Lv J, et al: Efficacy of immunotherapy in
patients with oncogene-driven non-small-cell lung cancer: A
systematic review and meta-analysis. Ther Adv Med Oncol.
16:175883592312250362024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gray JE, Villegas A, Daniel D, Vicente D,
Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, et al:
Three-year overall survival with durvalumab after chemoradiotherapy
in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 15:288–293.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Neumann M, Murphy N and Seetharamu N: The
evolving role of PD-L1 inhibition in non-small cell lung cancer: A
review of durvalumab and avelumab. Cancer Med J. 5:31–45.
2022.PubMed/NCBI
|
|
37
|
Faehling M, Schumann C, Christopoulos P,
Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt
P, Steger F, et al: Durvalumab after definitive chemoradiotherapy
in locally advanced unresectable non-small cell lung cancer
(NSCLC): Real-world data on survival and safety from the German
expanded-access program (EAP). Lung Cancer. 150:114–122. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Postmus PE, Kerr KM, Oudkerk M, Senan S,
Waller DA, Vansteenkiste J, Escriu C and Peters S; ESMO Guidelines
Committee, : Early and locally advanced non-small-cell lung cancer
(NSCLC): ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 28 (Suppl_4):iv1–iv21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M,
et al: NCCN GUIDELINES® insights: Non-small cell lung
cancer, version 2.2023. J Natl Compr Canc Netw. 21:340–350. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Faivre-Finn C, Vicente D, Kurata T,
Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC,
Reck M, Senan S, et al: Four-year survival with durvalumab after
chemoradiotherapy in stage III NSCLC-an update From the PACIFIC
trial. J Thorac Oncol. 16:860–867. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Y, Tian Y, Zheng L, Sun X, Zhao Z,
Zheng Y and Tian J: Efficacy and safety of consolidation durvalumab
after chemoradiation therapy for stage III non-small-cell lung
cancer: A systematic review, meta-analysis, and meta-regression of
real-world studies. Front Pharmacol. 14:11039272023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Waterhouse D, Yong C, Frankart A, Brannman
L, Mulrooney T, Robert N, Aguilar KM, Ndukum J and Cotarla I:
Durvalumab real-world treatment patterns and outcomes in patients
with stage III non-small-cell lung cancer treated in a US community
setting. Future Oncol. 19:1905–1916. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Filippi AR, Bar J, Chouaid C, Christoph
DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao
S, et al: Real-world outcomes with durvalumab after
chemoradiotherapy in patients with unresectable stage III NSCLC:
Interim analysis of overall survival from PACIFIC-R. ESMO Open.
9:1034642024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin
Q, Wu G, Cui J, Chang J, Cheng Y, et al: Sugemalimab versus placebo
after concurrent or sequential chemoradiotherapy in patients with
locally advanced, unresectable, stage III non-small-cell lung
cancer in China (GEMSTONE-301): Interim results of a randomised,
double-blind, multicentre, phase 3 trial. Lancet Oncol. 23:209–219.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Garassino MC, Mazieres J, Reck M, Chouaid
C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D,
Migliorino MR, et al: Durvalumab after sequential chemoradiotherapy
in stage III, unresectable NSCLC: The phase 2 PACIFIC-6 trial. J
Thorac Oncol. 17:1415–1427. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Durm GA, Jabbour SK, Althouse SK, Liu Z,
Sadiq AA, Zon RT, Jalal SI, Kloecker GH, Williamson MJ, Reckamp KL,
et al: A phase 2 trial of consolidation pembrolizumab following
concurrent chemoradiation for patients with unresectable stage III
non-small cell lung cancer: Hoosier cancer research network LUN
14–179. Cancer. 126:4353–4361. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rao S, Min L, Zhao J, Su J and Ye L:
Efficacy of consolidation of immune checkpoint inhibitor after
chemoradiation for unresectable, locally advanced PD-L1 negative
non-small cell lung cancer: A systematic review and meta-analysis.
Oncol Lett. 27:2422024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Remon J, Levy A, Gille R, Martel-Lafay I,
Bortolot M, Hendriks LEL, Faivre-Finn C, Leighl N, Reck M and Pérol
M: Unresectable stage III non-small-cell lung cancer: State of the
art and challenges. Nat Rev Clin Oncol.
9:10.1038/s41571–025-01080-4. 2025.
|
|
49
|
Weisman M, Durm G, Shields MD, Hanna NH,
Althouse S and Lautenschlaeger T: evaluation of radiation
pneumonitis in a phase 2 study of consolidation immunotherapy with
nivolumab and ipilimumab or nivolumab alone following concurrent
chemoradiation therapy for unresectable stage IIIA/IIIB non-small
cell Lung Cancer. Int J Rad Oncol, Biol, Phys. 121:720–727. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Barlesi F, Cho BC, Goldberg SB, Yoh K,
Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M and
Aggarwal C: PACIFIC-9: Phase III trial of durvalumab + oleclumab or
monalizumab in unresectable stage III non-small-cell lung cancer.
Future Oncol. 20:2137–2147. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Peters S, Felip E, Dafni U, Tufman A,
Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, et
al: Progression-free and overall survival for concurrent nivolumab
with standard concurrent chemoradiotherapy in locally advanced
stage IIIA-B NSCLC: Results from the European thoracic oncology
platform NICOLAS phase II trial (European Thoracic Oncology
Platform 6–14). J Thorac Oncol. 16:278–288. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu Y, Yao L, Kalhor N, Carter BW, Altan
M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, et
al: Final efficacy outcomes of atezolizumab with chemoradiation for
unresectable NSCLC: The phase II DETERRED trial. Lung Cancer.
174:112–117. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM, Chau I, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jabbour SK, Lee KH, Frost N, Breder V,
Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A,
Houghton B, et al: Pembrolizumab plus concurrent chemoradiation
therapy in patients with unresectable, locally advanced, stage III
non-small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized
trial. JAMA Oncol. 7:1–9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jabbour SK, Cho BC, Bria E, Kato T, Bhosle
J, Gainor JF, Reguart N, Wang L, Morgensztern D, Shentu Y, et al:
Rationale and design of the phase III KEYLYNK-012 Study of
pembrolizumab and concurrent chemoradiotherapy followed by
pembrolizumab with or without olaparib for stage III non-small-cell
lung cancer. Clin Lung Cancer. 23:e342–e346. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jabbour SK, Berman AT, Decker RH, Lin Y,
Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB II,
Bradley JD, et al: Phase 1 trial of pembrolizumab administered
concurrently with chemoradiotherapy for locally advanced non-small
cell lung cancer: A nonrandomized controlled trial. JAMA Oncol.
6:848–855. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Formenti SC and Demaria S: Combining
radiotherapy and cancer immunotherapy: A paradigm shift. J Natl
Cancer Inst. 105:256–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ross HJ, Kozono D, Wang XF, Urbanic JJ,
Williams TM, Nelson GD, Carbone DP, Chung D, Robb R, Byun W, et al:
Atezolizumab before and after chemoradiation for unresectable stage
III non-small cell lung cancer: A phase II nonrandomized controlled
trial. JAMA Oncol. 10:1212–1219. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker
M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E,
Juan-Vidal O, et al: First-line nivolumab plus ipilimumab combined
with two cycles of chemotherapy in patients with non-small-cell
lung cancer (CheckMate 9LA): An international, randomised,
open-label, phase 3 trial. Lancet Oncol. 22:198–211. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jiang P, Mao Z, Wang Q, Jia X, Geng L, Xu
H, Jiang L, Yang C, Jiao M and Guo H: An indirect comparison
between nivolumab + ipilimumab + two cycles of chemotherapy vs.
pembrolizumab + chemotherapy as first-line treatment for metastatic
non-small cell lung cancer. Front Oncol. 11:6981992021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ohri N, Jolly S, Cooper BT, Kabarriti R,
Bodner WR, Klein J, Guha C, Viswanathan S, Shum E, Sabari JK, et
al: Selective personalized radioimmunotherapy for locally advanced
non-small-cell lung cancer trial (SPRINT). J Clin Oncol.
42:562–570. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mouri A, Kisohara A, Morita R, Ko R,
Nakagawa T, Makiguchi T, Isobe K, Ishikawa N, Kondo T, Akiyama M,
et al: A phase II study of daily carboplatin plus irradiation
followed by durvalumab therapy for older adults (≥75 years) with
unresectable III non-small-cell lung cancer and performance status
of 2: NEJ039A. ESMO Open. 9:1039392024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bozorgmehr F, Chung I, Christopoulos P,
Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M and Rieken
S: Correction: Thoracic radiotherapy plus Durvalumab in elderly
and/or frail NSCLC stage III patients unfit for
chemotherapy-employing optimized (hypofractionated) radiotherapy to
foster durvalumab efficacy: Study protocol of the TRADE-hypo trial.
BMC Cancer. 23:7402023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
De Ruysscher D, Ramalingam S, Urbanic J,
Gerber DE, Tan DSW, Cai J, Li A and Peters S: CheckMate 73L: A
phase 3 study comparing nivolumab plus concurrent chemoradiotherapy
followed by nivolumab with or without ipilimumab versus concurrent
chemoradiotherapy followed by durvalumab for previously untreated,
locally advanced stage III non-small-cell lung cancer. Clin Lung
Cancer. 23:e264–e268. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hastings K, Yu HA, Wei W, Sanchez-Vega F,
DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, et al:
EGFR mutation subtypes and response to immune checkpoint blockade
treatment in non-small-cell lung cancer. Ann Oncol. 30:1311–1320.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gainor JF, Shaw AT, Sequist LV, Fu X,
Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et
al: EGFR mutations and ALK rearrangements are associated with low
response rates to PD-1 pathway blockade in non-small cell lung
cancer: A retrospective analysis. Clin Cancer Res. 22:4585–4593.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhu L, He W, Xie C, Shu Y, Zhang C and Zhu
Y: Efficacy and safety of immune checkpoint inhibitors for EGFR
mutated non-small cell lung cancer: A network meta-analysis. Front
Immunol. 15:15124682024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lu S, Kato T, Dong X, Ahn MJ, Quang LV,
Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, et al:
Osimertinib after chemoradiotherapy in Stage III EGFR-mutated
NSCLC. N Engl J Med. 391:585–597. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Durm G, Mamdani H, Althouse S, Perkins S,
Jabbour SK, Ganti AK, Jalal S, Chesney J, Naidoo J, Hrinczenko B,
et al: Randomized phase II study of consolidation immunotherapy
with nivolumab and ipilimumab or nivolumab alone following
concurrent chemoradiotherapy for unresectable stage IIIA/IIIB
non-small-cell lung cancer (NSCLC): Big ten cancer research
consortium LUN16-081. J Immunother Cancer. 13:e0103162025.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Gyawali B, Hey SP and Kesselheim AS:
Assessment of the clinical benefit of cancer drugs receiving
accelerated approval. JAMA Intern Med. 179:906–913. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Martins F, Sofiya L, Sykiotis GP, Lamine
F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A,
Guex-Crosier Y, et al: Adverse effects of immune-checkpoint
inhibitors: Epidemiology, management and surveillance. Nat Rev Clin
Oncol. 16:563–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Robert C: A decade of immune-checkpoint
inhibitors in cancer therapy. Nat Commun. 11:38012020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Di Federico A, Alden SL, Smithy JW,
Ricciuti B, Alessi JV, Wang X, Pecci F, Lamberti G, Gandhi MM, Vaz
VR, et al: Intrapatient variation in PD-L1 expression and tumor
mutational burden and the impact on outcomes to immune checkpoint
inhibitor therapy in patients with non-small-cell lung cancer. Ann
Oncol. 35:902–913. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Amrane K, Geier M, Corre R, Léna H,
Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, et
al: First-line pembrolizumab for non-small cell lung cancer
patients with PD-L1 ≥50% in a multicenter real-life cohort: The
PEMBREIZH study. Cancer Med. 9:2309–2316. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Shigeta N, Murakami S, Yokose T, Isaka T,
Shinada K, Nagashima T, Adachi H, Shigefuku S, Murakami K, Miura J,
et al: Comparison of SP263 and 22C3 pharmDx assays to test
programmed death ligand-1 (PD-L1) expression in surgically resected
non-small cell lung cancer. Thorac Cancer. 15:1343–1349. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Rimm DL, Han G, Taube JM, Yi ES, Bridge
JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, et al: A
prospective, multi-institutional, pathologist-based assessment of 4
immunohistochemistry assays for PD-L1 expression in non-small cell
lung cancer. JAMA Oncol. 3:1051–1058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Moding EJ, Liu Y, Nabet BY, Chabon JJ,
Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, et al:
Circulating tumor DNA dynamics predict benefit from consolidation
immunotherapy in locally advanced non-small cell lung cancer. Nat
Cancer. 1:176–183. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wang Y, Wang W, Zhang T, Yang Y, Wang J,
Li C, Xu X, Wu Y, Jiang Y, Duan J, et al: Dynamic bTMB combined
with residual ctDNA improves survival prediction in locally
advanced NSCLC patients with chemoradiotherapy and consolidation
immunotherapy. J Natl Cancer Cent. 4:177–187. 2024.PubMed/NCBI
|
|
81
|
Wang Y, Zhang T, Yang Y, Wang J, Li C, Xu
X, Wu Y, Jiang Y, Duan J, Wang L and Bi N: Longitudinal circulating
tumour DNA dynamics predict failure patterns and efficacy of
consolidation immunotherapy after chemoradiotherapy in locally
advanced non-small-cell lung cancer. Clin Transl Med. 14:e16192024.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
McGrail DJ, Pilié PG, Rashid NU, Voorwerk
L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, et
al: High tumor mutation burden fails to predict immune checkpoint
blockade response across all cancer types. Ann Oncol. 32:661–672.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ricciuti B, Wang X, Alessi JV, Rizvi H,
Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, et al:
Association of high tumor mutation burden in non-small cell lung
cancers with increased immune infiltration and improved clinical
outcomes of PD-L1 blockade Across PD-L1 expression levels. JAMA
Oncol. 8:1160–1168. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Klein C, Brinkmann U, Reichert JM and
Kontermann RE: The present and future of bispecific antibodies for
cancer therapy. Nat Rev Drug Discov. 23:301–319. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tanaka A and Sakaguchi S: Regulatory T
cells in cancer immunotherapy. Cell Res. 27:109–118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Mountzios G, Saw SPL, Hendriks L, Menis J,
Cascone T, Arrieta O, Naidoo J, Koutoukoglou P, Cani M, Lefevre A,
et al: Antibody-drug conjugates in NSCLC with actionable genomic
alterations: Optimizing smart delivery of chemotherapy to the
target. Cancer Treat Rev. 134:1029022025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sands J, Ahn MJ, Lisberg A, Cho BC,
Blumenschein G Jr, Shum E, Tostivint EP, Goto Y, Yoh K, Heist R, et
al: Datopotamab deruxtecan in advanced or metastatic non-small cell
lung cancer with actionable genomic alterations: Results from the
phase II TROPION-lung05 study. J Clin Oncol. 43:1254–1265. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares
L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, et
al: Amivantamab plus chemotherapy in NSCLC with EGFR exon 20
insertions. N Engl J Med. 389:2039–2051. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wen J, Cui W, Yin X, Chen Y, Liu A, Wang Q
and Meng X: Application and future prospects of bispecific
antibodies in the treatment of non-small cell lung cancer. Cancer
Biol Med. 22:348–375. 2025.PubMed/NCBI
|
|
91
|
Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S,
Yang S, Xu T, Liu Y, Wang N, et al: KN046, a bispecific antibody
against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment
for metastatic NSCLC: A multicenter phase 2 trial. Cell reports.
Medicine. 5:1014702024.PubMed/NCBI
|
|
92
|
Ma Y, Xue J, Zhao Y, Zhang Y, Huang Y,
Yang Y, Fang W, Guo Y, Li Q, Ge X, et al: Phase I trial of KN046, a
novel bispecific antibody targeting PD-L1 and CTLA-4 in patients
with advanced solid tumors. J Immunother Cancer. 11:e0066542023.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Levy BP, Paz-Ares LG, Lin CC, Herbert S,
Yang TY, Tolcher AW, Lou Y, Zenke Y, Cortinovis D, Felip E, et al:
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus
pembrolizumab (pembro) with or without platinum chemotherapy
(Pt-CT) as first-line (1 L) therapy for advanced non-small cell
lung cancer (aNSCLC). J Clin Oncol. 43 (16_suppl):S85012025.
View Article : Google Scholar
|
|
94
|
Okamoto I, Kuyama S, Girard N, Lu S,
Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, et al:
TROPION-lung07: Phase III study of Dato-DXd + pembrolizumab ±
platinum-based chemotherapy as 1L therapy for advanced
non-small-cell lung cancer. Future Oncol. 20:2927–2936. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Gulley JL, Schlom J, Barcellos-Hoff MH,
Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I and Moustakas A:
Dual inhibition of TGF-β and PD-L1: A novel approach to cancer
treatment. Mol Oncol. 16:2117–2134. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wei Q, Yang T, Zhang Z, Wang F, Yang Y,
Zhu J, Zhu X, Li Y, Xing Y, Lu Y, et al: Perivascular
Niche-resident alveolar macrophages promote interstitial
pneumonitis related to trastuzumab deruxtecan treatment. Cancer
Res. 85:2081–2099. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Demaria S, Ng B, Devitt ML, Babb JS,
Kawashima N, Liebes L and Formenti SC: Ionizing radiation
inhibition of distant untreated tumors (abscopal effect) is immune
mediated. Int J Radiat Oncol Biol Phys. 58:862–870. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Barber GN: STING: Infection, inflammation
and cancer. Nat Rev Immunol. 15:760–770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Corrales L, Glickman LH, McWhirter SM,
Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong
JJ, et al: Direct activation of STING in the tumor microenvironment
leads to potent and systemic tumor regression and immunity. Cell
Rep. 11:1018–1030. 2015. View Article : Google Scholar : PubMed/NCBI
|
